Department of Oncology, Medical Centre of Pediatric, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No 107 Yanjiang Road, Guangzhou, Guangdong, 510120, China.
BMC Cancer. 2023 Jul 17;23(1):670. doi: 10.1186/s12885-023-11159-9.
Neuroblastoma (NB) is a childhood malignant tumor,50% of high-risk NB children still have recurrence, and the long-term survival rate is very low. NB tumors expressing high levels of BDNF/TrkB are associated with poor survival outcomes.In this study, we show that the trends of serum concentration of BDNF at different growth stages after birth, and explore the relationship with NB replase.
In experiment 1, 87 subjects were enrolled and divided into four groups, neonates group、 children group、adults group and NB patients. The distribution of serum concentration of BDNF by ELISA. In experiment 2, we studied BDNF in stage 4 NB patients to determine their frequency, correlation with clinical parameters, and prognostic impact.
First, we identified that serum BDNF concentration decreased from the newborn to childhood in healthy subjects, while it was relatively high in children(age > 1 year) with NB. In the second phase our studies showed no significant increase in serum BDNF concentration in these NB patients, with adverse pathologic features, large tumor maximum diameter, and MYCN amplification. After comprehensive treatment, levels of BDNF gradually increased in children with recurrence and decreased in the remission group. High serum BDNF concentration was associated with relapse. Of 21 stage 4 neuroblastoma patients, adopted a comprehensive treatment approach including ATO-basic modified chemotherapy, traditional radiotherapy,stem cell transplatation and immunotherapy. 76% of alive patients having > 3 years follow-up.
The aim is to show that BDNF is a predictor of recurrence risk of NB.
神经母细胞瘤（NB）是一种儿童期恶性肿瘤，50%的高危 NB 儿童仍有复发，长期生存率非常低。NB 肿瘤表达高水平的 BDNF/TrkB 与不良生存结果相关。在这项研究中，我们显示了出生后不同生长阶段血清 BDNF 浓度的趋势，并探讨了与 NB 复发的关系。
在实验 1 中，纳入了 87 名受试者，并分为四组：新生儿组、儿童组、成人组和 NB 患者组。通过 ELISA 测定血清 BDNF 的分布。在实验 2 中，我们研究了 4 期 NB 患者的 BDNF，以确定其频率、与临床参数的相关性和预后影响。
首先，我们发现健康受试者的血清 BDNF 浓度从新生儿期到儿童期逐渐降低，而患有 NB 的儿童（年龄>1 岁）的血清 BDNF 浓度相对较高。在第二阶段，我们的研究表明，这些 NB 患者的血清 BDNF 浓度没有明显增加，这些患者具有不良的病理特征、大肿瘤最大直径和 MYCN 扩增。经过综合治疗，复发患儿的 BDNF 水平逐渐升高，缓解组则逐渐降低。高血清 BDNF 浓度与复发相关。在 21 名 4 期神经母细胞瘤患者中，采用 ATO-基础改良化疗、传统放疗、干细胞移植和免疫治疗等综合治疗方法。21 名患者中有 76%（16 名）有超过 3 年的随访。
本研究旨在表明 BDNF 是 NB 复发风险的预测因子。
